Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Neoplasm Metastasis 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Small Cell Lung Carcinoma 2Neurofibrosarcoma 2Lung Neoplasms 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Dermatofibrosarcoma 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor - Protocol Specific 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Osteosarcoma 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hypertension 1Histiocytoma 1

Interventions

temsirolimus 1ridaforolimus 1pazopanib 1Surveys and Questionnaires 1Pemetrexed 1Lenalidomide 1Crizotinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Cancers × pazopanib × Clear all
NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
178 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡